Abstract
Pseudomonas aeruginosa is a prevalent pathogenic species reported with severe nosocomial infections. P. aeruginosa infections gain significant concern due to the greater morbidity and mortality coupled with the development of multidrug resistance phenomenon. Furthermore, they are potentially participating in the development of infections to different organs of the human and possibly evade from the host immune defence mechanism. P. aeruginosa involves in the productions several virulence factors which makes the bacterium remains as potential life-threatening pathogen. Additionally, biofilm formation behaviours of P. aeruginosa offer windows to evade different adverse environmental conditions and initiation of adaptation process according to the stress condition and deliver highly resistance strain. The current antibiotics used to combat the Pseudomonas infection are gradually losing their efficacy in controlling the bacterial infections due to the development of the resistance mechanism within the bacterial system. The different resistance mechanisms including intrinsic, acquired and adaptive resistance are supporting the P. aeruginosa for the development of high resistance against several antimicrobial agents. Recently, several alternative therapeutic options were reported such as interference in quorum sensing of P. aeruginosa, phage therapy and development of antimicrobial peptides alternative therapeutic options against antibiotics with limited incidence of resistance development. This chapter overviews the pathogenesis and drug resistance development in P. aeruginosa and also covers the recently available therapeutic alternatives to combat Pseudomonas infection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarts M-A, Hancock JN, Heyland D, Marshall JC (2003) Antibiotics for ventilator-associated pneumonia. In: Aarts M-A (ed) The Cochrane database of systematic reviews. Wiley, Chichester
Ahmed MN, Porse A, Sommer MOA et al (2018) Evolution of antibiotic resistance in biofilm and planktonic Pseudomonas aeruginosa populations exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 62:1–12. https://doi.org/10.1128/AAC.00320-18
Al-Dahmoshi HOM, Al-Khafaji NS, Abdulzahra Jeyad A et al (2018) Molecular detection of some virulence traits among Pseudomonas aeruginosa isolates, Hilla-Iraq. Biomed Pharmacol J 11:835–842. https://doi.org/10.13005/bpj/1439
Alhazmi A (2015) Pseudomonas aeruginosa – pathogenesis and pathogenic mechanisms. Int J Biol 7:44–67. https://doi.org/10.5539/ijb.v7n2p44
Alionte LG, Cannon BM, White CD et al (2001) Pseudomonas aeruginosa LasA protease and corneal infections. Curr Eye Res 22:266–271. https://doi.org/10.1076/ceyr.22.4.266.5509
Anantharajah A, Mingeot-Leclercq M-P, Van Bambeke F (2016) Targeting the type three secretion system in Pseudomonas aeruginosa. Trends Pharmacol Sci 37:734–749. https://doi.org/10.1016/j.tips.2016.05.011
Asfour H (2018) Anti-quorum sensing natural compounds. J Microsc Ultrastruct 6(1):1. https://doi.org/10.4103/JMAU.JMAU_10_18
Azam MW, Khan AU (2019) Updates on the pathogenicity status of Pseudomonas aeruginosa. Drug Discov Today 24:350–359. https://doi.org/10.1016/j.drudis.2018.07.003
Bacha K, Tariku Y, Gebreyesus F et al (2016) Antimicrobial and anti-quorum sensing activities of selected medicinal plants of Ethiopia: implication for development of potent antimicrobial agents. BMC Microbiol 16:139. https://doi.org/10.1186/s12866-016-0765-9
Bai AJ, Rai VR (2011) Bacterial quorum sensing and food industry. Compr Rev Food Sci Food Saf 10:183–193. https://doi.org/10.1111/j.1541-4337.2011.00150.x
Bassetti M, Vena A, Croxatto A et al (2018) How to manage Pseudomonas aeruginosa infections. Drugs Context 7:1–18. https://doi.org/10.7573/dic.212527
Battle SE, Rello J, Hauser AR (2009) Genomic islands of Pseudomonas aeruginosa. FEMS Microbiol Lett 290:70–78. https://doi.org/10.1111/j.1574-6968.2008.01406.x
Beaussart A, Baker AE, Kuchma SL et al (2014) Nanoscale adhesion forces of Pseudomonas aeruginosa type IV pili. ACS Nano 8:10723–10733. https://doi.org/10.1021/nn5044383
Bhagirath AY, Li Y, Somayajula D et al (2016) Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med 16:174. https://doi.org/10.1186/s12890-016-0339-5
Bhardwaj AK, Vinothkumar K, Rajpara N (2013) Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov 8:68–83. https://doi.org/10.2174/1574891X11308010012
Bjarnsholt T, Jensen PØ, Burmølle M et al (2005) Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151:373–383. https://doi.org/10.1099/mic.0.27463-0
Bouglé A, Foucrier A, Dupont H et al (2017) Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. Trials 18:37. https://doi.org/10.1186/s13063-017-1780-3
Breidenstein EBM, de la Fuente-Núñez C, Hancock REW (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419–426. https://doi.org/10.1016/j.tim.2011.04.005
Bucior I, Pielage JF, Engel JN (2012) Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog 8:e1002616. https://doi.org/10.1371/journal.ppat.1002616
Burkinshaw BJ, Strynadka NCJ (2014) Assembly and structure of the T3SS. Biochim Biophys Acta, Mol Cell Res 1843:1649–1663. https://doi.org/10.1016/j.bbamcr.2014.01.035
Burstein D, Satanower S, Simovitch M et al (2015) Novel type III effectors in Pseudomonas aeruginosa. MBio 6:2–7. https://doi.org/10.1128/mBio.00161-15
Cafora M, Deflorian G, Forti F et al (2019) Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Sci Rep 9:1527. https://doi.org/10.1038/s41598-018-37636-x
Campodonico VL, Llosa NJ, Grout M et al (2010) Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun 78:746–755. https://doi.org/10.1128/IAI.00806-09
Carter MQ, Chen J, Lory S (2010) The Pseudomonas aeruginosa pathogenicity island PAPI-1 is transferred via a novel type IV pilus. J Bacteriol 192:3249–3258. https://doi.org/10.1128/JB.00041-10
Cascales E (2017) Inside the chamber of secrets of the type III secretion system. Cell 168:949–951. https://doi.org/10.1016/j.cell.2017.02.028
Chan BK, Turner PE, Kim S et al (2018) Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018:60–66. https://doi.org/10.1093/emph/eoy005
Chatterjee M, Anju CP, Biswas L et al (2016) Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol 306:48–58. https://doi.org/10.1016/j.ijmm.2015.11.004
Christensen LD, van Gennip M, Jakobsen TH et al (2012) Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother 67:1198–1206. https://doi.org/10.1093/jac/dks002
Christie PJ, Whitaker N, González-Rivera C (2014) Mechanism and structure of the bacterial type IV secretion systems. Biochim Biophys Acta, Mol Cell Res 1843:1578–1591. https://doi.org/10.1016/j.bbamcr.2013.12.019
Colbert B, Kumari H, Piñon A et al (2018) Alginate-regulating genes are identified in the clinical cystic fibrosis isolate of Pseudomonas aeruginosa PA2192. bioRxiv:1–33. https://doi.org/10.1101/319004
da Silva Filho LVRF, Ferreira FDA, Reis FJC et al (2013) Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J Bras Pneumol 39:495–512. https://doi.org/10.1590/S1806-37132013000400015
de la Fuente-Núñez C, Reffuveille F, Fernández L, Hancock RE (2013) Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 16:580–589. https://doi.org/10.1016/j.mib.2013.06.013
Defoirdt T (2018) Quorum-sensing systems as targets for antivirulence therapy. Trends Microbiol 26:313–328. https://doi.org/10.1016/j.tim.2017.10.005
Depluverez S, Devos S, Devreese B (2016) The role of bacterial secretion systems in the virulence of gram-negative airway pathogens associated with cystic fibrosis. Front Microbiol 7:1–8. https://doi.org/10.3389/fmicb.2016.01336
Dostert M, Belanger CR, Hancock REW (2019) Design and assessment of anti-biofilm peptides: steps toward clinical application. J Innate Immun 11:193–204. https://doi.org/10.1159/000491497
Feldman M, Bryan R, Rajan S et al (1998) Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 66:43–51
Fila G, Krychowiak M, Rychlowski M et al (2018) Antimicrobial blue light photoinactivation of Pseudomonas aeruginosa: quorum sensing signaling molecules, biofilm formation and pathogenicity. J Biophotonics 11:e201800079. https://doi.org/10.1002/jbio.201800079
Franklin MJ, Nivens DE, Weadge JT, Lynne Howell P (2011) Biosynthesis of the Pseudomonas aeruginosa extracellular polysaccharides, alginate, Pel, and Psl. Front Microbiol 2:1–16. https://doi.org/10.3389/fmicb.2011.00167
Friedman ND, Temkin E, Carmeli Y (2016) The negative impact of antibiotic resistance. Clin Microbiol Infect 22:416–422. https://doi.org/10.1016/j.cmi.2015.12.002
Fujii A, Seki M, Higashiguchi M et al (2014) Community-acquired, hospital-acquired, and healthcare-associated pneumonia caused by Pseudomonas aeruginosa. Respir Med Case Rep 12:30–33. https://doi.org/10.1016/j.rmcr.2014.03.002
Furiga A, Lajoie B, El Hage S et al (2016) Impairment of Pseudomonas aeruginosa biofilm resistance to antibiotics by combining the drugs with a new quorum-sensing inhibitor. Antimicrob Agents Chemother 60:1676–1686. https://doi.org/10.1128/AAC.02533-15
Galle M, Carpentier I, Beyaert R (2012) Structure and function of the type III secretion system of Pseudomonas aeruginosa. Curr Protein Pept Sci 13:831–842. https://doi.org/10.2174/138920312804871210
Garvey MI, Bradley CW, Tracey J, Oppenheim B (2016) Continued transmission of Pseudomonas aeruginosa from a wash hand basin tap in a critical care unit. J Hosp Infect 94:8–12. https://doi.org/10.1016/j.jhin.2016.05.004
Gellatly SL, Hancock REW (2013) Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159–173. https://doi.org/10.1111/2049-632X.12033
Goldberg JB, Pier GB (1996) Pseudomonas aeruginosa lipopolysaccharides and pathogenesis. Trends Microbiol 4:490–494. https://doi.org/10.1016/S0966-842X(97)82911-3
Gonzalez MR, Fleuchot B, Lauciello L et al (2016) Effect of human burn wound exudate on Pseudomonas aeruginosa virulence. mSphere 1:1–14. https://doi.org/10.1128/mSphere.00111-15
Grassi L, Batoni G, Ostyn L et al (2019) The antimicrobial peptide lin-SB056-1 and its dendrimeric derivative prevent Pseudomonas aeruginosa biofilm formation in physiologically relevant models of chronic infections. Front Microbiol 10:1–14. https://doi.org/10.3389/fmicb.2019.00198
Harmsen M, Yang L, Pamp SJ, Tolker-Nielsen T (2010) An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal. FEMS Immunol Med Microbiol 59:253–268. https://doi.org/10.1111/j.1574-695X.2010.00690.x
Hauser AR (2011) Pseudomonas aeruginosa: so many virulence factors, so little time∗. Crit Care Med 39:2193–2194. https://doi.org/10.1097/CCM.0b013e318221742d
Herwald H, Egesten A (2009) Bacterial proteases disarming host Defense. J Innate Immun 1:69–69. https://doi.org/10.1159/000181143
Hill C, Mills S, Ross RP (2018) Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback? Future Microbiol 13:711–726. https://doi.org/10.2217/fmb-2017-0261
Hirsch EB, Tam VH (2010) Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 10:441–451. https://doi.org/10.1586/erp.10.49
Hnamte S, Parasuraman P, Ranganathan S et al (2019) Mosloflavone attenuates the quorum sensing controlled virulence phenotypes and biofilm formation in Pseudomonas aeruginosa PAO1: in vitro, in vivo and in silico approach. Microb Pathog 131:128–134. https://doi.org/10.1016/j.micpath.2019.04.005
Hobden JA (2002) Pseudomonas aeruginosa proteases and corneal virulence. DNA Cell Biol 21:391–396. https://doi.org/10.1089/10445490260099674
Huang Z, Jiang Y, Liang J (2011) Pathogenesis could be one of the anti-cheating mechanisms for Pseudomonas aeruginosa society. Med Hypotheses 76:166–168. https://doi.org/10.1016/j.mehy.2010.09.007
Hurley MN, Cámara M, Smyth AR (2012) Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J 40:1014–1023. https://doi.org/10.1183/09031936.00042012
Ingmer H, Brøndsted L (2009) Proteases in bacterial pathogenesis. Res Microbiol 160:704–710. https://doi.org/10.1016/j.resmic.2009.08.017
Izoré T, Job V, Dessen A (2011) Biogenesis, regulation, and targeting of the type III secretion system. Structure 19:603–612. https://doi.org/10.1016/j.str.2011.03.015
Jamal M, Ahmad W, Andleeb S et al (2018) Bacterial biofilm and associated infections. J Chin Med Assoc 81:7–11. https://doi.org/10.1016/j.jcma.2017.07.012
Jeevanandam J, Chan YS, Danquah MK (2016) Nano-formulations of drugs: recent developments, impact and challenges. Biochimie 128–129:99–112. https://doi.org/10.1016/j.biochi.2016.07.008
Juhas M (2015) Type IV secretion systems and genomic islands-mediated horizontal gene transfer in Pseudomonas and Haemophilus. Microbiol Res 170:10–17. https://doi.org/10.1016/j.micres.2014.06.007
Juhas M, Crook DW, Hood DW (2008) Type IV secretion systems: tools of bacterial horizontal gene transfer and virulence. Cell Microbiol 10:2377–2386. https://doi.org/10.1111/j.1462-5822.2008.01187.x
Kalaiarasan E, Thirumalaswamy K, Harish BN et al (2017) Inhibition of quorum sensing-controlled biofilm formation in Pseudomonas aeruginosa by quorum-sensing inhibitors. Microb Pathog 111:99–107. https://doi.org/10.1016/j.micpath.2017.08.017
Kalia VC, Patel SKS, Kang YC, Lee J-K (2019) Quorum sensing inhibitors as antipathogens: biotechnological applications. Biotechnol Adv 37:68–90. https://doi.org/10.1016/j.biotechadv.2018.11.006
Kariminik A, Baseri-Salehi M, Kheirkhah B (2017) Pseudomonas aeruginosa quorum sensing modulates immune responses: an updated review article. Immunol Lett 190:1–6. https://doi.org/10.1016/j.imlet.2017.07.002
Kerr KG, Snelling AM (2009) Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 73:338–344. https://doi.org/10.1016/j.jhin.2009.04.020
Kibret KT, Moges Y, Memiah P, Biadgilign S (2017) Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty 6:7. https://doi.org/10.1186/s40249-016-0214-x
King JD, KocÃncová D, Westman EL, Lam JS (2009) Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa. Innate Immun 15:261–312. https://doi.org/10.1177/1753425909106436
Klockgether J, Tümmler B (2017) Recent advances in understanding Pseudomonas aeruginosa as a pathogen. F1000Res 6:1261. https://doi.org/10.12688/f1000research.10506.1
Koh CL, Sam CK, Yin WF et al (2013) Plant-derived natural products as sources of anti-quorum sensing compounds. Sensors (Basel) 13:6217–6228. https://doi.org/10.3390/s130506217
Kohlenberg A, Weitzel-Kage D, van der Linden P et al (2010) Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J Hosp Infect 74:350–357. https://doi.org/10.1016/j.jhin.2009.10.024
Kung VL, Ozer EA, Hauser AR (2010) The accessory genome of Pseudomonas aeruginosa. Microbiol Mol Biol Rev 74:621–641. https://doi.org/10.1128/MMBR.00027-10
Lantz MS (1997) Are bacterial proteases important virulence factors? J Periodontal Res 32:126–132. https://doi.org/10.1111/j.1600-0765.1997.tb01393.x
Law N, Logan C, Yung G et al (2019) Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47:665–668. https://doi.org/10.1007/s15010-019-01319-0
Lee DG, Urbach JM, Wu G et al (2006) Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol 7:R90. https://doi.org/10.1186/gb-2006-7-10-r90
Limoli DH, Whitfield GB, Kitao T et al (2017) Pseudomonas aeruginosa alginate overproduction promotes coexistence with Staphylococcus aureus in a model of cystic fibrosis respiratory infection. MBio 8:1–18. https://doi.org/10.1128/mBio.00186-17
Lorè NI, Cigana C, De Fino I et al (2012) Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One 7:e35648. https://doi.org/10.1371/journal.pone.0035648
Ma Q, Zhai Y, Schneider JC et al (2003) Protein secretion systems of Pseudomonas aeruginosa and P. fluorescens. Biochim Biophys Acta Biomembr 1611:223–233. https://doi.org/10.1016/S0005-2736(03)00059-2
Macia MD, Rojo-Molinero E, Oliver A (2014) Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect 20:981–990. https://doi.org/10.1111/1469-0691.12651
Maldonado RF, Sá-Correia I, Valvano MA (2016) Lipopolysaccharide modification in gram-negative bacteria during chronic infection. FEMS Microbiol Rev 40:480–493. https://doi.org/10.1093/femsre/fuw007
Markou P, Apidianakis Y (2014) Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer. Front Cell Infect Microbiol 3:1–5. https://doi.org/10.3389/fcimb.2013.00115
Matsumoto K (2004) Role of bacterial proteases in pseudomonal and serratial keratitis. Biol Chem 385:1007–1016. https://doi.org/10.1515/BC.2004.131
Maurice NM, Bedi B, Sadikot RT (2018) Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections. Am J Respir Cell Mol Biol 58:428–439. https://doi.org/10.1165/rcmb.2017-0321TR
McCaslin CA, Petrusca DN, Poirier C et al (2015) Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance. J Cyst Fibros 14:70–77. https://doi.org/10.1016/j.jcf.2014.06.009
Micek ST, Kollef MH, Torres A et al (2015) Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification. Infect Control Hosp Epidemiol 36:1190–1197. https://doi.org/10.1017/ice.2015.167
Michalska M, Wolf P (2015) Pseudomonas exotoxin A: optimized by evolution for effective killing. Front Microbiol 6:1–7. https://doi.org/10.3389/fmicb.2015.00963
Mofazzal Jahromi MA, Sahandi Zangabad P, Moosavi Basri SM et al (2018) Nanomedicine and advanced technologies for burns: preventing infection and facilitating wound healing. Adv Drug Deliv Rev 123:33–64. https://doi.org/10.1016/j.addr.2017.08.001
Morlon-Guyot J, Mere J, Bonhoure A, Beaumelle B (2009) Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication. Infect Immun 77:3090–3099. https://doi.org/10.1128/IAI.01390-08
Musicki B, Liu T, Lagoda GA et al (2009) Endothelial nitric oxide synthase regulation in female genital tract structures. J Sex Med 6:247–253. https://doi.org/10.1111/j.1743-6109.2008.01122.x
Nguyen L, Garcia J, Gruenberg K, MacDougall C (2018) Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon? Curr Infect Dis Rep 20:23. https://doi.org/10.1007/s11908-018-0629-6
Niederman MS (2010) Hospital-acquired pneumonia, health care–associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis 51:S12–S17. https://doi.org/10.1086/653035
Oliver A, Mulet X, López-Causapé C, Juan C (2015) The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21–22:41–59. https://doi.org/10.1016/j.drup.2015.08.002
Overhage J, Lewenza S, Marr AK, Hancock REW (2007) Identification of genes involved in swarming motility using a Pseudomonas aeruginosa PAO1 mini-Tn5-lux mutant library. J Bacteriol 189:2164–2169. https://doi.org/10.1128/JB.01623-06
Palanisamy N, Ferina N, Amirulhusni A et al (2014) Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J Nanobiotechnology 12:2. https://doi.org/10.1186/1477-3155-12-2
Pang Z, Raudonis R, Glick BR et al (2019) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37:177–192. https://doi.org/10.1016/j.biotechadv.2018.11.013
Pena C, Cabot G, Gomez-Zorrilla S et al (2015) Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 60:539–548. https://doi.org/10.1093/cid/ciu866
Pier G (2007) Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol 297:277–295. https://doi.org/10.1016/j.ijmm.2007.03.012
Pillar CM, Hobden JA (2002) Pseudomonas aeruginosa exotoxin A and keratitis in mice. Investig Ophthalmol Vis Sci 43:1437–1444
Pires DP, Vilas Boas D, Sillankorva S, Azeredo J (2015) Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89:7449–7456. https://doi.org/10.1128/jvi.00385-15
Pletzer D, Hancock REW (2016) Antibiofilm peptides: potential as broad-spectrum agents. J Bacteriol 198:2572–2578. https://doi.org/10.1128/JB.00017-16
Puhar A, Sansonetti PJ (2014) Type III secretion system. Curr Biol 24:R784–R791. https://doi.org/10.1016/j.cub.2014.07.016
Rafla K, Tredget EE (2011) Infection control in the burn unit. Burns 37:5–15. https://doi.org/10.1016/j.burns.2009.06.198
Rasamiravaka T, Labtani Q, Duez P, El Jaziri M (2015) The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. Biomed Res Int 2015:1–17. https://doi.org/10.1155/2015/759348
Rohde C, Wittmann J, Kutter E (2018) Bacteriophages: a therapy concept against multi-drug–resistant bacteria. Surg Infect 19:737–744. https://doi.org/10.1089/sur.2018.184
Rossi Gonçalves I, Dantas RCC, Ferreira ML et al (2017) Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation. Braz J Microbiol 48:211–217. https://doi.org/10.1016/j.bjm.2016.11.004
Salter SJ (2015) Keeping an eye on P. aeruginosa. Nat Rev Microbiol 13:69–69. https://doi.org/10.1038/nrmicro3422
Satpathy S, Sen SK, Pattanaik S, Raut S (2016) Review on bacterial biofilm: an universal cause of contamination. Biocatal Agric Biotechnol 7:56–66. https://doi.org/10.1016/j.bcab.2016.05.002
Silby MW, Winstanley C, Godfrey SAC et al (2011) Pseudomonas genomes: diverse and adaptable. FEMS Microbiol Rev 35:652–680. https://doi.org/10.1111/j.1574-6976.2011.00269.x
Simões D, Miguel SP, Ribeiro MP et al (2018) Recent advances on antimicrobial wound dressing: a review. Eur J Pharm Biopharm 127:130–141. https://doi.org/10.1016/j.ejpb.2018.02.022
Smith WD, Bardin E, Cameron L et al (2017) Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiol Lett 364:1–9. https://doi.org/10.1093/femsle/fnx121
Sousa A, Pereira M (2014) Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. Pathogens 3:680–703. https://doi.org/10.3390/pathogens3030680
Stefani S, Campana S, Cariani L et al (2017) Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol 307:353–362. https://doi.org/10.1016/j.ijmm.2017.07.004
Streeter K, Katouli M (2016) Pseudomonas aeruginosa: a review of their pathogenesis and prevalence in clinical settings and the environment. Infect Epidemiol Med 2:25–32. https://doi.org/10.18869/modares.iem.2.1.25
Taccetti G, Campana S, Neri AS et al (2008) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. J Chemother 20:166–169. https://doi.org/10.1179/joc.2008.20.2.166
Taylor PK, Yeung ATY, Hancock REW (2014) Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol 191:121–130. https://doi.org/10.1016/j.jbiotec.2014.09.003
Teerapo K, Roytrakul S, Sistayanarain A, Kunthalert D (2019) A scorpion venom peptide derivative BmKn–22 with potent antibiofilm activity against Pseudomonas aeruginosa. PLoS One 14:e0218479. https://doi.org/10.1371/journal.pone.0218479
Trokter M, Felisberto-Rodrigues C, Christie PJ, Waksman G (2014) Recent advances in the structural and molecular biology of type IV secretion systems. Curr Opin Struct Biol 27:16–23. https://doi.org/10.1016/j.sbi.2014.02.006
Tumbarello M, De Pascale G, Trecarichi EM et al (2013) Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 39:682–692. https://doi.org/10.1007/s00134-013-2828-9
Valentini M, Gonzalez D, Mavridou DA, Filloux A (2018) Lifestyle transitions and adaptive pathogenesis of Pseudomonas aeruginosa. Curr Opin Microbiol 41:15–20. https://doi.org/10.1016/j.mib.2017.11.006
Van Acker H, Van Dijck P, Coenye T (2014) Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol 22:326–333. https://doi.org/10.1016/j.tim.2014.02.001
Wagner S, Sommer R, Hinsberger S et al (2016) Novel strategies for the treatment of Pseudomonas aeruginosa infections. J Med Chem 59:5929–5969. https://doi.org/10.1021/acs.jmedchem.5b01698
Wang Y, Beekman J, Hew J et al (2018) Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev 123:3–17. https://doi.org/10.1016/j.addr.2017.09.018
Waters EM, Neill DR, Kaman B et al (2017) Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72:666–667. https://doi.org/10.1136/thoraxjnl-2016-209265
Werneburg M, Zerbe K, Juhas M et al (2012) Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics. Chembiochem 13:1767–1775. https://doi.org/10.1002/cbic.201200276
Wiehlmann L, Wagner G, Cramer N et al (2007) Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci 104:8101–8106. https://doi.org/10.1073/pnas.0609213104
Wilke M, Grube R, Bodmann K (2011) Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. Eur J Med Res 16:315. https://doi.org/10.1186/2047-783X-16-7-315
Wolfgang MC, Kulasekara BR, Liang X et al (2003) Conservation of genome content and virulence determinants among clinical and environmental isolates of Pseudomonas aeruginosa. Proc Natl Acad Sci 100:8484–8489. https://doi.org/10.1073/pnas.0832438100
Wu Y-L, Yang X-Y, Ding X-X et al (2019) Exposure to infected/colonized roommates and prior room occupants increases the risks of healthcare-associated infections with the same organism. J Hosp Infect 101:231–239. https://doi.org/10.1016/j.jhin.2018.10.014
Yamazaki A, Li J, Zeng Q et al (2012) Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system. Antimicrob Agents Chemother 56:36–43. https://doi.org/10.1128/AAC.00732-11
Yelin I, Kishony R (2018) Antibiotic resistance. Cell 172:1136–1136.e1. https://doi.org/10.1016/j.cell.2018.02.018
Zaidi S, Misba L, Khan AU (2017) Nano-therapeutics: a revolution in infection control in post antibiotic era. Nanomedicine 13:2281–2301. https://doi.org/10.1016/j.nano.2017.06.015
Zhu M, Zhao J, Kang H et al (2016) Modulation of type III secretion system in Pseudomonas aeruginosa: involvement of the PA4857 gene product. Front Microbiol 7:1–13. https://doi.org/10.3389/fmicb.2016.00007
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Parasuraman, P., Syed, A., Siddhardha, B. (2020). Pathogenesis and Drug Resistance of Pseudomonas aeruginosa. In: Siddhardha, B., Dyavaiah, M., Syed, A. (eds) Model Organisms for Microbial Pathogenesis, Biofilm Formation and Antimicrobial Drug Discovery. Springer, Singapore. https://doi.org/10.1007/978-981-15-1695-5_13
Download citation
DOI: https://doi.org/10.1007/978-981-15-1695-5_13
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1694-8
Online ISBN: 978-981-15-1695-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)